{
    "clinical_study": {
        "@rank": "33605", 
        "arm_group": [
            {
                "arm_group_label": "BI 416970 single rising dose part", 
                "arm_group_type": "Experimental", 
                "description": "single rising dose given as tablet"
            }, 
            {
                "arm_group_label": "BI 416970 bioavailability part", 
                "arm_group_type": "Experimental", 
                "description": "given as tablet and solution"
            }, 
            {
                "arm_group_label": "BI 416970 geno-part", 
                "arm_group_type": "Experimental", 
                "description": "given as tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the safety and tolerability of BI 416970 and to assess the pharmacokinetics\n      (PK) of single rising doses of BI 416970. A further objective is to explore the relative\n      bioavailability of tablet fasted versus PfOS fasted and of tablet fasted versus tablet fed\n      and to assess the influence of CYP2C9 phenotype on the PK of BI 416970."
        }, 
        "brief_title": "To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers and Investigate Relative Bioavailability of BI 416970 as Well as Assess of Safety and Exposure of BI 416970 in CYP2C9 Genotyped Volunteers", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy males according to the investigator's assessment, based on a complete medical\n             history including a physical examination, vital signs (Blood Pressure, Pulse Rate),\n             12-lead electrocardiogram, and clinical laboratory\n\n          -  Age 18 to 50 years (incl.)\n\n          -  Body Mass Index 18.5 to 29.9 kg/m2 (incl.)\n\n          -  Signed and dated written informed consent prior to admission to the study in\n             accordance with GCP and local legislation\n\n          -  Known genotype of CYP2C9 isoenzyme\n\n        Exclusion criteria:\n\n          -  Any finding in the medical examination (including Blood Pressure, Pulse Rate or\n             Electrocardiogram) is deviating from normal and judged as clinically relevant by the\n             investigator\n\n          -  Repeated measurement of systolic blood pressure greater than 140 mmHg, diastolic\n             blood pressure greater than 90 mmHg, or pulse rate outside the range of 50 to 90 mmHg\n\n          -  Any laboratory value outside the reference range that the investigator considers to\n             be of clinical relevance\n\n          -  Any evidence of a concomitant disease judged as clinically relevant by the\n             investigator\n\n          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,\n             immunological or hormonal disorders\n\n          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial\n             medication\n\n          -  Diseases of the central nervous system (such as epilepsy), other peripheral\n             neurological disorders or psychiatric disorders"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093819", 
            "org_study_id": "1345.1", 
            "secondary_id": "2013-003560-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 416970 geno-part", 
                "description": "geno-part", 
                "intervention_name": "BI 416970", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 416970 bioavailability part", 
                "description": "different dose formulations", 
                "intervention_name": "BI 416970", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 416970 single rising dose part", 
                "description": "single rising doses", 
                "intervention_name": "Placebo to BI 416970", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 416970 single rising dose part", 
                "description": "single rising doses", 
                "intervention_name": "BI 416970", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Biberach", 
                    "country": "Germany"
                }, 
                "name": "1345.1.1 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 416970 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, Investigation of Relative Bioavailability of BI 416970 (Open-label, Randomised, Three-way Cross-over) and Assessment of Safety and Exposure of BI 416970 in CYP2C9 Genotyped Volunteers (Open-label, Single-dose)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with drug-related adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 7 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093819"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 7 weeks"
            }, 
            {
                "measure": "AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 7 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}